References

Multiple myeloma therapy: emerging trends and challenges

10.3390/cancers14174082 · 2022 · External reference

TAK-079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion

2017 · External reference

Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology

10.1152/physrev.00035.2007 · 2008 · External reference

CD38: an immunomodulatory molecule in inflammation and autoimmunity

10.3389/fimmu.2020.597959 · 2020 · External reference

Is there a future for anti-CD38 antibody therapy in systemic autoimmune diseases?

10.3390/cells9010077 · 2019 · External reference

Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

10.1186/s13075-018-1578-z · 2018 · External reference

CD38 antibodies in multiple myeloma: back to the future

10.1182/blood-2017-06-740944 · 2018 · External reference

The anti-CD38 monoclonal antibody TAK-079 depletes antibody secreting cells from normal and SLE patients [abstract]

2016 · External reference

A reduction in B, T, and natural killer cells expressing CD38 by TAK-079 inhibits the induction and progression of collagen-induced arthritis in cynomolgus monkeys

10.1124/jpet.119.256602 · 2019 · External reference

Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma

10.3324/haematol.2020.268656 · 2021 · External reference

Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects

10.1111/bcp.14241 · 2020 · External reference

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

10.1200/jco.2013.48.7934 · 2014 · External reference

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

10.1182/blood-2010-10-299487 · 2011 · External reference

International uniform response criteria for multiple myeloma

10.1038/sj.leu.2404284 · 2006 · External reference

Anti CD38 monoclonal antibodies for multiple myeloma treatment

10.1080/21645515.2022.2052658 · 2022 · External reference

NCCN Guidelines Insights: multiple myeloma, version 3.2022

10.6004/jnccn.2022.0002 · 2022 · External reference

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(†)

10.1016/j.annonc.2020.11.014 · 2021 · External reference

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

10.1182/blood-2016-09-740787 · 2017 · External reference

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

10.1182/blood-2019-02-895193 · 2019 · External reference

Targeting CD38 with daratumumab monotherapy in multiple myeloma

10.1056/nejmoa1506348 · 2015 · External reference

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

10.1182/blood-2016-07-726729 · 2016 · External reference

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

10.1182/blood.2019000667 · 2019 · External reference

Past, present, and a glance into the future of multiple myeloma treatment

10.3390/ph16030415 · 2023 · External reference

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

10.1016/s2352-3026(19)30249-2 · 2020 · External reference

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

10.1016/s0140-6736(19)32556-5 · 2019 · External reference

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

10.1016/s2352-3026(20)30070-3 · 2020 · External reference

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

10.1016/s1470-2045(21)00128-5 · 2021 · External reference

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

10.1038/s41375-019-0435-7 · 2019 · External reference

Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update

10.7326/m22-1460 · 2022 · External reference